Valuation: Geron Corporation

Market Cap 100.72Cr 87Cr 82Cr 75Cr 141.34Cr 9.59TCr 143.18Cr 957.48Cr 375.76Cr 4.79TCr 378.16Cr 369.94Cr 16TCr P/E 2026 *
-98.1x
P/E 2027 * 17.4x
Enterprise Value 100.72Cr 87Cr 82Cr 75Cr 141.34Cr 9.59TCr 143.18Cr 957.48Cr 375.76Cr 4.79TCr 378.16Cr 369.94Cr 16TCr EV / Sales 2026 *
4.2x
EV / Sales 2027 * 2.94x
Free-Float
99.77%
Yield 2026 *
-
Yield 2027 * -
1 day-2.23%
1 week+18.99%
Current month+18.99%
1 month+3.02%
3 months+5.14%
6 months-4.66%
Current year+16.29%
1 week 1.24
Extreme 1.24
1.63
1 month 1.22
Extreme 1.22
1.63
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Free

Director

6,103 0.0010%
17/02/26 Fiscal year

Chief Financial Officer

17,24,855 0.2702%
17/02/26 Free

Chief Technology Officer

22,20,000 0.3478%
Change 5-day change 1-year change 3-year change Capi.($)
-2.23%+18.99%+18.08%-47.43% 100.72Cr
-3.25%+13.72%+52.49%+88.86% 6.29TCr
+1.57%+2.77%+32.96%+73.17% 5.43TCr
+3.08%+1.85%-17.14%-6.34% 2.29TCr
-2.50%+30.88%+18.07%+490.08% 2.87TCr
+10.83%+21.32%+45.03%+2.02% 2.16TCr
+7.14%+8.26%+39.09%-20.82% 1.78TCr
-3.88%+20.98%+201.07%+350.94% 1.65TCr
+6.20%+12.16%+28.51%+629.05% 1.55TCr
+1.78%+0.25%+42.19%+162.54% 1.31TCr
Average +1.87%+7.39%+46.04%+172.21% 2.54TCr
Weighted average by Cap. +1.15%+7.65%+44.09%+160.31%

Financials

2026 *2027 *
Net sales 24Cr 21Cr 20Cr 18Cr 34Cr 2.29TCr 34Cr 228.16Cr 90Cr 1.14TCr 90Cr 88Cr 3.8TCr 34Cr 30Cr 28Cr 25Cr 48Cr 3.26TCr 49Cr 325.48Cr 127.73Cr 1.63TCr 128.55Cr 125.75Cr 5.42TCr
Net income -1.1Cr -95.12L -89.07L -81.48L -1.54Cr -104.42Cr -1.56Cr -10Cr -4.09Cr -52Cr -4.12Cr -4.03Cr -173.65Cr 6.56Cr 5.69Cr 5.33Cr 4.88Cr 9.21Cr 625.05Cr 9.33Cr 62Cr 24Cr 312.3Cr 25Cr 24Cr 1.04TCr
Net Debt - -
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
07/26/07 $1.535 -2.23% 11,27,870
06/26/06 $1.570 -3.68% 1,62,07,172
05/26/05 $1.630 +21.64% 3,60,80,015
04/26/04 $1.340 +4.69% 1,34,64,407
03/26/03 $1.280 -0.78% 1,95,60,705
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.570USD
Average target price
4.250USD
Spread / Average Target
+170.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock